Anixa Biosciences, Inc. (ANIX)

$4.46

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol ANIX
Price $4.46
Beta 0.972
Volume Avg. 0.05M
Market Cap 137.907M
Shares () -
52 Week Range 2.3-6.25
1y Target Est -
DCF Unlevered ANIX DCF ->
DCF Levered ANIX LDCF ->
ROE -42.86% Strong Sell
ROA -44.70% Strong Sell
Operating Margin -
Debt / Equity 7.62% Neutral
P/E -
P/B 4.66 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ANIX news


Dr. Amit Kumar
Healthcare
Biotechnology
NASDAQ Capital Market

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.